Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284606 | 0.88 | OPRD1 (0.44) | OPRD1OPRK1CHRM1DPP8DPP4 | |
| SCHEMBL3284592 | 0.88 | OPRD1 (0.44) | OPRD1OPRK1CHRM1DPP8DPP4 | |
| SCHEMBL3278136 | 0.88 | OPRD1 (0.44) | OPRD1OPRK1CHRM1SMYD3DPP8 | |
| SCHEMBL3278143 | 0.88 | OPRD1 (0.44) | OPRD1OPRK1CHRM1SMYD3DPP8 | |
| SCHEMBL3285684 | 0.87 | CHRM1 (0.46) | OPRD1OPRK1CHRM1DPP8DPP4 | |
| SCHEMBL3279110 | 0.87 | OPRD1 (0.41) | OPRD1CHRM1DPP4AKT1 | |
| SCHEMBL3279033 | 0.86 | DPP8 (0.48) | OPRD1CHRM1DPP8 | |
| SCHEMBL3279578 | 0.85 | L3MBTL3 (0.43) | OPRD1CHRM1SMYD3DPP8DPP4 | |
| SCHEMBL3279588 | 0.85 | L3MBTL3 (0.43) | OPRD1CHRM1SMYD3DPP8DPP4 | |
| SCHEMBL3277831 | 0.82 | OPRD1 (0.41) | OPRD1OPRK1CHRM1DPP4AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152171-A1 | CGRP Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7700589-B2 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-20070244099-A1 | CGRP Antagonists | RUDOLF KLAUS | 2007-10-18 | — | — | US | disclosed |
| US-20040132716-A1 | CGRP antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244099-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | OPRD1 7/4885OPRK1 6/4885CHRM1 347/4885 |
| US-20100152171-A1 | CGRP Antagonists | CALCRL, OPRL1, CALCA | OPRD1 7/4885OPRK1 6/4885CHRM1 347/4885 |
| US-20040132716-A1 | CGRP antagonists | OPRL1, HTR1D, CALCA | OPRD1 11/4885OPRK1 10/4885CHRM1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.